Alignment Healthcare shares appear undervalued, with a Discounted Cash Flow model estimating intrinsic value at about $43.72 per share compared to the current price of $24.01, implying a roughly 45.1% discount. The stock has returned about 321.2% over three years, yet the DCF analysis, based on trailing free cash flow of approximately $204.1 million, suggests the market is pricing the senior-focused health insurer below its projected cash generation. Additionally, Alignment Healthcare trades on a price-to-sales ratio of about 1.2 times, below the healthcare industry average of around 1.5 times and a peer group average of about 2.3 times, while screening as undervalued in five of six valuation tests. The key question remains whether the company can scale its membership and control medical costs without reimbursement or execution setbacks that could challenge the apparent discount.
Alignment Healthcare LLCDCF analysis suggests 45% undervaluation and stock trades below industry P/S ratios, indicating potential upside.